According to an announcement on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on February 26, the Investigational New Drug (IND) application for DIFF Biotech's "Lyophilized Nasal Spray Live Attenuated Influenza Vaccine" has been officially accepted (Acceptance No.: CXSL2500176). This vaccine is indicated for the prevention of influenza caused by relevant types of influenza viruses.

From June 25 to 27, 2024, Dr. Jiasheng Song, founder of DIFF Biotech, was invited to attend the 2024 U.S.-China Collaborative Innovation Project Promotion Conference. Under the theme “Harmonious Hangzhou, Creating and Sharing the Future,” the event brought together entrepreneurs, investors, academics, and industry experts from both China and the United States to discuss future opportunities. T

"In the golden autumn of October, osmanthus blooms fill the air with their fragrance." On October 26, 2023, Difference (Hefei) Biotechnology Co., Ltd. (hereinafter referred to as "DIFF(Hefei) Biotech") grandly held its opening ceremony in the High-Tech Zone of Hefei, Anhui Province.

On November 30, 2022, Zhejiang Difference Biological Technology Co., Ltd established its wholly-owned subsidiary, DIFFERENCE BIOTECH PTE. LTD. (hereinafter referred to as "Difference (Singapore)"), in Singapore. This subsidiary serves as a window to provide differentiated, high-value scientific and technological services and products to global clients. It is responsible for the internationalization of DIFF Biotech's products and technologies.